Pharmacy Times®
Specialty Pharmacy Times
  • Specialty Drugs: Year in Review 2014
  • Are the Political Winds Shifting for Medical Marijuana?
  • The New Paradigm in Specialty: Payer Formulary Control?
  • Managing Care and Costs for Orphan Conditions
  • CMS Under Increased Pressure to Make Accurate Payments for Prescription Drugs
  • Why a Holistic, Technology-Enabled Treatment Approach Is Necessary to Address Hepatitis C–Related Liver Disease
New Class of Drugs May Eventually Treat Over 30 Diseases
Davy James, Managing Editor
Compounds that prevent protein aggregation may lead to therapy for conditions such as cancer and diabetes.
Ovarian Cancer Drug Added to Chemotherapy Extends Overall Survival
Davy James, Managing Editor
Standard chemotherapy plus bevacizumab extends survival by a median of 5 months.
Amgen Seeks Expanded Use for Multiple Myeloma Drug
Krystle Vermes
Kyprolis has already been approved for patients who failed at least 2 previous therapies.
Harvoni by Gilead Sciences, Inc
Michael R. Page, PharmD, RPh
Harvoni is an all-oral treatment of chronic hepatitis C genotype 1 infection in adults.
Viekira Pak by AbbVie Inc
Michael R. Page, PharmD, RPh
Viekira Pak is an all-oral regimen that has been approved by the FDA for the treatment of genotype 1 chronic hepatitis C virus infection.
Featured Video
Drug Adherence Trends in Specialty Pharmacy
Michael R. Hess, attorney with Bass Berry & Sims and outside general counsel to many of the largest independent specialty pharmacy companies, discusses adherence trends specialty pharmacies need to be aware of.
Industry Guide
We've created this Industry Guide with close to 300 companies and organizations as a one-stop guide for industry stakeholders in the specialty pharmacy space.
Current Issue
Conference Calendar
â—„        April 2015        â–º
Featured Company Profile
Pharmacy Times
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2015
Intellisphere, LLC. All Rights Reserved.